Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin combinations in HER2-altered NSCLC
NCT05847764Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05847764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05847764.